FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183405237> ?p ?o ?g. }

• W3183405237 endingPage "e002474" @default.
• W3183405237 startingPage "e002474" @default.
• W3183405237 abstract "Background Statins preferentially promote tumor-specific apoptosis by depleting isoprenoid such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. However, statins have not yet been approved for clinical cancer treatment due, in part, to poor understanding of molecular determinants on statin sensitivity. Here, we investigated the potential of statins to elicit enhanced immunogenicity of KRAS -mutant ( KRAS mut ) tumors. Methods The immunogenicity of treated cancer cells was determined by western blot, flow cytometry and confocal microscopy. The immunotherapeutic efficacy of mono or combination therapy using statin was assessed in KRAS mut tumor models, including syngeneic colorectal cancer and genetically engineered lung and pancreatic tumors. Using NanoString analysis, we analyzed how statin influenced the gene signatures associated with the antigen presentation of dendritic cells in vivo and evaluated whether statin could induce CD8+ T-cell immunity. Multiplex immunohistochemistry was performed to better understand the complicated tumor-immune microenvironment. Results Statin-mediated inhibition of KRAS prenylation provoked severe endoplasmic reticulum (ER) stress by attenuating the anti-ER stress effect of KRAS mutation, thereby resulting in the immunogenic cell death (ICD) of KRAS mut cancer cells. Moreover, statin-mediated ICD enhanced the cross-priming ability of dendritic cells, thereby provoking CD8+ T-cell immune responses against KRAS mut tumors. Combination therapy using statin and oxaliplatin, an ICD inducer, significantly enhanced the immunogenicity of KRAS mut tumors and promoted tumor-specific immunity in syngeneic and genetically engineered KRAS mut tumor models. Along with immune-checkpoint inhibitors, the abovementioned combination therapy overcame resistance to PD-1 blockade therapies, improving the survival rate of KRAS mut tumor models. Conclusions Our findings suggest that KRAS mutation could be a molecular target for statins to elicit potent tumor-specific immunity." @default.
• W3183405237 created "2021-08-02" @default.
• W3183405237 creator A5005480922 @default.
• W3183405237 creator A5009476522 @default.
• W3183405237 creator A5011310359 @default.
• W3183405237 creator A5012090769 @default.
• W3183405237 creator A5020087184 @default.
• W3183405237 creator A5026717849 @default.
• W3183405237 creator A5027210423 @default.
• W3183405237 creator A5029245218 @default.
• W3183405237 creator A5038019961 @default.
• W3183405237 creator A5044200599 @default.
• W3183405237 creator A5051046735 @default.
• W3183405237 creator A5056540176 @default.
• W3183405237 creator A5064423861 @default.
• W3183405237 creator A5064921066 @default.
• W3183405237 creator A5072097110 @default.
• W3183405237 creator A5082460884 @default.
• W3183405237 creator A5083559838 @default.
• W3183405237 creator A5089005412 @default.
• W3183405237 date "2021-07-01" @default.
• W3183405237 modified "2023-10-18" @default.
• W3183405237 title "Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer" @default.
• W3183405237 cites W1804040094 @default.
• W3183405237 cites W1967329857 @default.
• W3183405237 cites W1975702431 @default.
• W3183405237 cites W1977315768 @default.
• W3183405237 cites W1991189794 @default.
• W3183405237 cites W2002252224 @default.
• W3183405237 cites W2011425688 @default.
• W3183405237 cites W2012743071 @default.
• W3183405237 cites W2016612145 @default.
• W3183405237 cites W2038338711 @default.
• W3183405237 cites W2051626784 @default.
• W3183405237 cites W2072073513 @default.
• W3183405237 cites W2081990599 @default.
• W3183405237 cites W2091103707 @default.
• W3183405237 cites W2095681827 @default.
• W3183405237 cites W2098749704 @default.
• W3183405237 cites W2120426523 @default.
• W3183405237 cites W2126564019 @default.
• W3183405237 cites W2126663928 @default.
• W3183405237 cites W2146622763 @default.
• W3183405237 cites W2166249402 @default.
• W3183405237 cites W2169820120 @default.
• W3183405237 cites W2252550602 @default.
• W3183405237 cites W2345520280 @default.
• W3183405237 cites W2358744153 @default.
• W3183405237 cites W2517092932 @default.
• W3183405237 cites W2563661701 @default.
• W3183405237 cites W2605630275 @default.
• W3183405237 cites W2772899582 @default.
• W3183405237 cites W2783899879 @default.
• W3183405237 cites W2787649310 @default.
• W3183405237 cites W2790541566 @default.
• W3183405237 cites W2796894486 @default.
• W3183405237 cites W2805379737 @default.
• W3183405237 cites W2892164007 @default.
• W3183405237 cites W2892819708 @default.
• W3183405237 cites W2897947119 @default.
• W3183405237 cites W2923531267 @default.
• W3183405237 cites W2941933382 @default.
• W3183405237 cites W2944980090 @default.
• W3183405237 cites W2969479281 @default.
• W3183405237 cites W2976327330 @default.
• W3183405237 cites W2982321167 @default.
• W3183405237 cites W3006554079 @default.
• W3183405237 cites W3040660865 @default.
• W3183405237 cites W3047618013 @default.
• W3183405237 cites W3083506235 @default.
• W3183405237 cites W3140388327 @default.
• W3183405237 cites W4362223089 @default.
• W3183405237 doi "https://doi.org/10.1136/jitc-2021-002474" @default.
• W3183405237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8327837" @default.
• W3183405237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34330763" @default.
• W3183405237 hasPublicationYear "2021" @default.
• W3183405237 type Work @default.
• W3183405237 sameAs 3183405237 @default.
• W3183405237 citedByCount "34" @default.
• W3183405237 countsByYear W31834052372021 @default.
• W3183405237 countsByYear W31834052372022 @default.
• W3183405237 countsByYear W31834052372023 @default.
• W3183405237 crossrefType "journal-article" @default.
• W3183405237 hasAuthorship W3183405237A5005480922 @default.
• W3183405237 hasAuthorship W3183405237A5009476522 @default.
• W3183405237 hasAuthorship W3183405237A5011310359 @default.
• W3183405237 hasAuthorship W3183405237A5012090769 @default.
• W3183405237 hasAuthorship W3183405237A5020087184 @default.
• W3183405237 hasAuthorship W3183405237A5026717849 @default.
• W3183405237 hasAuthorship W3183405237A5027210423 @default.
• W3183405237 hasAuthorship W3183405237A5029245218 @default.
• W3183405237 hasAuthorship W3183405237A5038019961 @default.
• W3183405237 hasAuthorship W3183405237A5044200599 @default.
• W3183405237 hasAuthorship W3183405237A5051046735 @default.
• W3183405237 hasAuthorship W3183405237A5056540176 @default.
• W3183405237 hasAuthorship W3183405237A5064423861 @default.
• W3183405237 hasAuthorship W3183405237A5064921066 @default.
• W3183405237 hasAuthorship W3183405237A5072097110 @default.

• next